Medicare's CAR-T Payment Change Helps the Entire Regenerative Medicine Field ... A Little Bit
Executive Summary
Alliance for Regenerative Medicine says CMS' plan to create new reimbursement category for CAR-T helps validate entire field, but it may not make it any easier for other products to navigate the payment landscape. ARM is prioritizing value-based payment legislation in its Congressional lobbying.
You may also be interested in...
Medicare CAR-T Payment Policy Walks Line Between Innovation and Cost Concerns
CMS proposes new DRG with higher average payment rate for CAR-T therapy but signals new technology add-on payments will no longer be awarded to supplement reimbursement.
New Payment Models For Curative Treatments Have CMS’ Attention, Verma Says
US Centers for Medicare and Medicaid Services administrator Seema Verma discusses solutions for handling the high cost of gene therapy and the Trump administration’s drug pricing agenda in briefing with reporters.
Reata’s Bardoxolone Shot Down, But US FDA Advisors Offers Suggestions For Improved Study
Advisory committee unanimously votes against bardoxolone for Alport syndrome, unconvinced drug slows progression of chronic kidney disease and concerned about safety signals suggesting it could make the disease worse. However, panel offers Reata suggestions for a better-designed trial.